Open AccessEvaluation of pediatric patients with јuvenile idiopathic arthritis treated with biological therapy Tocilizumab (Actemra)
Author(s) -
Marija Neskovska-Sumenkovska,
Aspazija Sofijanova,
Rozana Kacarska,
Konstandina Kuzevska-Maneva,
Beti Gjurkova Angelovska,
Valentina Jovanovska
Publication year - 2021
Publication title -
arhivi na javnoto zdravje
Language(s) - English
Resource type - Journals
ISSN - 1857-7148
DOI - 10.3889/aph.2021.6016
Subject(s) - tocilizumab , medicine , methotrexate , arthritis , therapeutic effect , disease , surgery , gastroenterology
Juvenile idiopathic arthritis (JIA) is the most common chronic disease in childhood. It manifests a heterogenic group of symptoms of arthritis, lasting at least 6 weeks and it appears before the age of 16. Patients who had no good therapeutic response to conventional therapy with Methotrexate were treated with biological therapy. The aim of this paper was to evaluate 9 patients who were receiving Tocilizumab at the Department of Rheumocardiology, University Clinic of Pediatric Diseases in Skopje. Materials and methods: Our study included 9 patients treated at our Department with biological therapy with Tocilizumab. Prior to initiation of the biological therapy, all patients underwent laboratory investigations, purified protein derivative (PPD) skin test for tuberculosis, X ray of the lungs and heart, and analysis of hepatitis markers. All patients were treated with amp. Actemra (tocilizumab) 8 mg/kg/tt i.v. Two of the patients had a severe form of the disease (one with severe systemic form and one with severe oligoarticular form of JIA). All presented patients had clinical remission of the disease. Conclusion: Therapy with tocilizumab in patients with juvenile idiopathic arthritis is a good therapeutic choice. The results obtained in our study have shown a significant therapeutic effect of tocilizumab even in severe forms of the disease.